Cellectar Biosciences (CLRB) Institutional Ownership $4.93 +0.11 (+2.20%) As of 11:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Cellectar Biosciences (NASDAQ:CLRB)CurrentInstitutional OwnershipPercentage16.41%Number ofInstitutional Buyers(last 12 months)11TotalInstitutional Inflows(last 12 months)$76.83MNumber ofInstitutional Sellers(last 12 months)4TotalInstitutional Outflows(last 12 months)$14.27M Get CLRB Insider Trade Alerts Want to know when executives and insiders are buying or selling Cellectar Biosciences stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data CLRB Institutional Buying and Selling by Quarter Cellectar Biosciences Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/13/2025 Riverview Capital Advisers LLC10,500$75K0.0%N/A0.580% 8/8/2025 Geode Capital Management LLC14,439$103K0.0%-96.7%0.798% 5/12/2025 Simplex Trading LLC173,129$54K0.0%+331.3%0.376% 5/8/2025 Baader Bank Aktiengesellschaft172,940$55K0.0%N/A0.375% 5/8/2025 XTX Topco Ltd104,323$33K0.0%+122.6%0.226% 4/23/2025 Sequoia Financial Advisors LLC203,260$64K0.0%+1,301.8%0.441% 2/17/2025 Squarepoint Ops LLC520,240$156K0.0%N/A1.129% 2/17/2025 Bank of America Corp DE206,783$62K0.0%+25.3%0.449% 2/13/2025 ADAR1 Capital Management LLC585,261$175K0.0%-42.7%1.270% 2/12/2025 JPMorgan Chase & Co.182,403$55K0.0%+687.3%0.396% Get the Latest News and Ratings for CLRB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter. 11/19/2024 Barclays PLC120,497$258K0.0%-30.0%0.292% 11/16/2024 Geode Capital Management LLC352,452$754K0.0%+3.3%0.869% 11/15/2024 Barclays PLC120,497$258K0.0%-30.0%0.297% 11/15/2024 XTX Topco Ltd53,022$113K0.0%-16.2%0.131% 11/6/2024 Oppenheimer & Co. Inc.12,500$27K0.0%N/A0.031% 10/30/2024 Rosalind Advisors Inc.3,671,550$7.86M4.9%+35.7%10.241% 10/22/2024 Sequoia Financial Advisors LLC23,800$51K0.0%N/A0.066% 8/20/2024 Nantahala Capital Management LLC1,833,325$4.58M0.3%-2.1%5.114% 8/16/2024 Coastal Bridge Advisors LLC11,000$28K0.0%-31.3%0.031% 8/12/2024 XTX Topco Ltd63,304$158K0.0%+432.4%0.177% 8/7/2024 AIGH Capital Management LLC3,036,187$7.59M2.4%+8.2%8.469% 7/12/2024 Rosalind Advisors Inc.2,705,616$6.76M5.0%+335.4%7.547% 5/10/2024 Vanguard Group Inc.1,191,081$4.74M0.0%+146.7%3.322% 4/25/2024 Rosalind Advisors Inc.621,478$2.47M2.3%-69.0%1.926% 2/14/2024 ADAR1 Capital Management LLC1,378,082$3.82M1.4%N/A11.213% 2/12/2024 AIGH Capital Management LLC1,915,220$5.31M2.1%+182.7%15.584% 2/9/2024 Worth Venture Partners LLC693,909$1.92M1.0%+148.6%5.646% 1/1/2024 Vanguard Group Inc.175,884$464K0.0%+2.3%1.431% 11/15/2023 Worth Venture Partners LLC279,123$737K0.4%-11.0%2.808% 11/15/2023 Acuta Capital Partners LLC121,300$320K0.2%N/A1.220% 11/13/2023 AIGH Capital Management LLC677,511$1.79M0.8%-16.7%6.816% 7/21/2023 1900 Wealth Management LLC18,000$35K0.0%+50.0%0.185% 2/16/2023 AIGH Capital Management LLC931,888$1.59M0.5%+434.3%9.924% 11/16/2022 Maven Securities LTD25,000$84K0.0%-93.8%0.266% 11/14/2022 Worth Venture Partners LLC41,636$140K0.1%-90.9%0.444% 11/14/2022 Maven Securities LTD25,000$84K0.0%-93.8%0.266% 11/3/2022ACT Capital Management LLC21,750$73K0.1%-90.0%0.356% 10/31/2022 1900 Wealth Management LLC12,000$40K0.0%N/A0.196% 5/12/2022 AIGH Capital Management LLC1,837,046$1.26M0.3%+104.9%3.007% 4/27/2022 1900 Wealth Management LLC120,000$83K0.0%+100.0%0.196% Capital Gains Tax Strategies for Seniors (Ad)Capital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holding investments longer to using tax-advantaged accounts and strategic loss offsetting, there are ways to reduce your exposure. SmartAsset outlines three capital gains tax strategies for seniors and offers a free tool to connect you with vetted fiduciary financial advisors who can help tailor these tactics to your situation.Click here to see the three strategies and get matched with a financial advisor today.2/14/2022 Maven Securities LTD400,000$266K0.0%-60.4%0.655% 2/10/2022 AIGH Capital Management LLC896,590$596K0.2%N/A1.467% 11/15/2021 Franklin Resources Inc.142,400$132K0.0%N/A0.233% 11/12/2021 Renaissance Technologies LLC447,074$414K0.0%-55.8%0.732% 11/5/2021 Cozad Asset Management Inc.51,000$47K0.0%+64.5%0.083% 9/17/2021 Virtu Financial LLC49,780$59K0.0%N/A0.081% 8/17/2021PVG Asset Management Corp193,510$230K0.7%+1,804.6%0.317% 8/16/2021 Maven Securities LTD650,000$793K0.0%-27.8%1.064% 8/16/2021 State Street Corp147,846$176K0.0%N/A0.242% 8/16/2021 Sabby Management LLC426,561$508K0.1%+9.6%0.698% 8/13/2021 Renaissance Technologies LLC1,011,268$1.20M0.0%+13.3%1.655% 8/13/2021QS Investors LLC142,400$170K0.0%N/A0.233% 8/13/2021 Geode Capital Management LLC397,170$472K0.0%+62.5%0.650% 8/13/2021 Vanguard Group Inc.1,874,584$2.23M0.0%+14.1%3.068% 8/5/2021 GSA Capital Partners LLP297,653$354K0.0%+90.0%0.564% 8/4/2021 Envestnet Asset Management Inc.104,385$124K0.0%+354.3%0.198% 8/2/2021 Advisor Group Holdings Inc.23,827$28K0.0%+221.4%0.045% (Data available from 1/1/2016 forward) CLRB Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CLRB shares? During the previous two years, 19 institutional investors and hedge funds held shares of Cellectar Biosciences. The most heavily invested institutionals were Rosalind Advisors Inc. ($7.86M), AIGH Capital Management LLC ($7.59M), Vanguard Group Inc. ($4.74M), Nantahala Capital Management LLC ($4.58M), Worth Venture Partners LLC ($1.92M), Acuta Capital Partners LLC ($320K), and Barclays PLC ($258K).Learn more on Cellectar Biosciences' institutional investors. What percentage of Cellectar Biosciences' stock is owned by institutional investors? 16.41% of Cellectar Biosciences' stock is owned by institutional investors. Learn more on CLRB's institutional investor holdings. Which institutional investors have been buying Cellectar Biosciences' stock? Of the 16 institutional investors that purchased Cellectar Biosciences' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Rosalind Advisors Inc. ($3.05M), AIGH Capital Management LLC ($1.47M), ADAR1 Capital Management LLC ($1.38M), Vanguard Group Inc. ($712.10K), Squarepoint Ops LLC ($520.24K), Worth Venture Partners LLC ($414.79K), and Sequoia Financial Advisors LLC ($212.56K). How much institutional buying is happening at Cellectar Biosciences? Institutional investors have bought a total of 2,297,311 shares in the last 24 months. This purchase volume represents approximately $76.83M in transactions. Which of Cellectar Biosciences' major shareholders have been selling company stock? The following institutional investors have sold Cellectar Biosciences stock in the last 24 months: ADAR1 Capital Management LLC ($436.90K), Geode Capital Management LLC ($428.99K), Barclays PLC ($103.40K), and XTX Topco Ltd ($10.28K). How much institutional selling is happening at Cellectar Biosciences? Institutional investors have sold a total of 979,567 shares in the last 24 months. This volume of shares sold represents approximately $14.27M in transactions. Related Companies ADVM Major Shareholders IFRX Major Shareholders HOWL Major Shareholders DRRX Major Shareholders DTIL Major Shareholders IZTC Major Shareholders IMA Major Shareholders CLNN Major Shareholders ATNM Major Shareholders PDSB Major Shareholders This page (NASDAQ:CLRB) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access